Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-02-27 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
2023年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023 Annual Performance Express Report" (年度业绩快报公告), which indicates it is a preliminary earnings announcement for the full year 2023. It contains key financial data such as revenue, net profit, earnings per share, and asset figures, but explicitly states that the data is preliminary and unaudited, with final audited figures to be disclosed in the full annual report. The document is relatively short (1676 characters) and serves as an initial earnings release rather than a full annual report or audited financial statement. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. FY 2023
2024-02-27 Chinese
2023年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is an announcement of the company's 2023 annual performance forecast, including preliminary financial data and explanations for expected profit decline. It explicitly states that the data is preliminary, unaudited, and that the final audited data will be disclosed in the 2023 annual report. The document is short (800 characters) and serves as a forecast or earnings guidance rather than a full financial report. It does not contain full financial statements or comprehensive analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of periodic financial results or forecasts. FY 2023
2024-02-27 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations of the company Inner Mongolia Datang Pharmaceutical Co., Ltd. It details the stock price deviation, investigation into possible causes, confirmation of no undisclosed material information, and a risk warning to investors. The document is short (1248 characters) and focuses on stock trading activity and regulatory compliance disclosures rather than financial results or management reports. It does not contain financial statements or detailed financial data. It is a typical regulatory announcement about stock price abnormality and related disclosures, fitting the category of Regulatory Filings (RNS).
2024-02-06 Chinese
关于药品安宫牛黄丸完成备案的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about the completion of a drug product filing with a regulatory authority (Inner Mongolia Drug Administration). It includes a statement about the impact on the company and a caution to investors. The document length is only 542 characters, indicating it is a brief announcement rather than a detailed report. There is no financial data, no detailed financial statements, or comprehensive analysis. It is not an annual or interim report, nor an earnings release. It is not a regulatory filing in the sense of officer certifications or compliance documents, but rather a regulatory announcement about product filing completion. Given the content and length, it fits best as a Regulatory Filing (RNS) which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2024-02-06 Chinese
关于“同泰永”品牌被认定为中华老字号的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement (518 characters) from a company about its brand being recognized as a 'Chinese Time-honored Brand' by several government departments. It contains no financial data, no mention of financial results, no regulatory filings, no meeting materials, no voting results, no management changes, no legal proceedings, no capital changes, and no other financial or governance report content. It is a general corporate announcement about brand recognition. Given the short length and content, it does not fit into any specific financial report category. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other categories.
2024-02-01 Chinese
股东增持股份进展公告
Transaction in Own Shares Classification · 95% confidence The document is titled as a "股东增持股份进展公告" which translates to "Shareholders' Share Increase Progress Announcement." It details the progress of shareholding increases by specific directors and executives, including the number of shares held before and after the increase, the method of increase, and the related risks. There is no financial statement or comprehensive financial data presented. The document is an announcement about transactions in the company's own shares by insiders (directors and executives). This fits the definition of "Transaction in Own Shares" (POS) rather than a full financial report or other categories. The document length is short (1817 characters), and it is a direct announcement of share transactions by company insiders, not a report or regulatory filing. Therefore, the correct classification is POS with high confidence.
2024-01-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.